These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16412970)

  • 1. Calcineurin nephrotoxicity.
    Williams D; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jan; 13(1):47-55. PubMed ID: 16412970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-toxicity immunosuppressive therapy in renal transplant].
    Scolari F; La Manna G; Comai G; Cappuccilli ML; Todeschini P; Ciavatti A; Persici E; Feliciangeli G; Stefoni S
    G Ital Nefrol; 2007; 24 Suppl 38():44-8. PubMed ID: 17922447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic allograft nephropathy.
    Baluja P; Haragsim L; Laszik Z
    Adv Chronic Kidney Dis; 2006 Jan; 13(1):56-61. PubMed ID: 16412971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.
    Martínez-Mier G; Méndez-López MT; Estrada-Oros J; Budar-Fernandez LF; Soto-González JI; Méndez-Machado GF; Viñas Dozal JC
    Arch Med Res; 2006 Jul; 37(5):635-8. PubMed ID: 16740435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive agents in organ transplantation: past, present, and future.
    Hong JC; Kahan BD
    Semin Nephrol; 2000 Mar; 20(2):108-25. PubMed ID: 10746855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
    Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity.
    Chang HR; Lee MH; Wen MC; Lian JD
    Transplant Proc; 2004 Nov; 36(9):2668-70. PubMed ID: 15621119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive strategies to improve outcomes of kidney transplantation.
    Tang IY; Meier-Kriesche HU; Kaplan B
    Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney dysfunction in the recipients of liver transplants.
    Wilkinson A; Pham PT
    Liver Transpl; 2005 Nov; (11 Suppl 2):S47-51. PubMed ID: 16237714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation.
    Danger R; Giral M; Soulillou JP; Brouard S
    Curr Opin Organ Transplant; 2008 Dec; 13(6):609-13. PubMed ID: 19060551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
    Schena FP; Maiorano A; Rossini M
    G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
    Issa N; Kukla A; Ibrahim HN
    Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.